Robin A. Eisch
YOU?
Author Swipe
View article: Treatment of indolent systemic mastocytosis with sarilumab is not supported in a randomized trial
Treatment of indolent systemic mastocytosis with sarilumab is not supported in a randomized trial Open
Results in this small trial did not support using sarilumab to treat this population and highlights the importance of double-blind randomized studies.
View article: Supplementary Figure 3 from Electrocardiographic Studies of Romidepsin Demonstrate Its Safety and Identify a Potential Role for K<sub>ATP</sub> Channel
Supplementary Figure 3 from Electrocardiographic Studies of Romidepsin Demonstrate Its Safety and Identify a Potential Role for K<sub>ATP</sub> Channel Open
Supplementary Figure 3 - PDF file 62K, Changes in mean heart rate during cycles 1 when patients taking betablockers were excluded
View article: Supplementary Figure 8 from Electrocardiographic Studies of Romidepsin Demonstrate Its Safety and Identify a Potential Role for K<sub>ATP</sub> Channel
Supplementary Figure 8 from Electrocardiographic Studies of Romidepsin Demonstrate Its Safety and Identify a Potential Role for K<sub>ATP</sub> Channel Open
Supplementary Figure 8 - PDF file 299K, Changes in mean heart rate during cycles 2 when patients taking betablockers were excluded
View article: Supplementary Figure 1 from Electrocardiographic Studies of Romidepsin Demonstrate Its Safety and Identify a Potential Role for K<sub>ATP</sub> Channel
Supplementary Figure 1 from Electrocardiographic Studies of Romidepsin Demonstrate Its Safety and Identify a Potential Role for K<sub>ATP</sub> Channel Open
Supplementary Figure 1 - PDF file 69K, Changes in heart rate observed for patients in the NIH cohort during cycle 1 days 1, 8 and 15
View article: Supplementary Figure Legends from Electrocardiographic Studies of Romidepsin Demonstrate Its Safety and Identify a Potential Role for K<sub>ATP</sub> Channel
Supplementary Figure Legends from Electrocardiographic Studies of Romidepsin Demonstrate Its Safety and Identify a Potential Role for K<sub>ATP</sub> Channel Open
Supplementary Figure Legends - PDF file 25K, Legends describing supplementary figures
View article: Supplementary Figure 5 from Electrocardiographic Studies of Romidepsin Demonstrate Its Safety and Identify a Potential Role for K<sub>ATP</sub> Channel
Supplementary Figure 5 from Electrocardiographic Studies of Romidepsin Demonstrate Its Safety and Identify a Potential Role for K<sub>ATP</sub> Channel Open
Supplementary Figure 5 - PDF file 60K, Changes in heart rate observed for patients in the NIH cohort during cycle 2 days 1, 8 and 15
View article: Supplementary Figure 5 from Electrocardiographic Studies of Romidepsin Demonstrate Its Safety and Identify a Potential Role for K<sub>ATP</sub> Channel
Supplementary Figure 5 from Electrocardiographic Studies of Romidepsin Demonstrate Its Safety and Identify a Potential Role for K<sub>ATP</sub> Channel Open
Supplementary Figure 5 - PDF file 60K, Changes in heart rate observed for patients in the NIH cohort during cycle 2 days 1, 8 and 15
View article: Supplemental Tables from Electrocardiographic Studies of Romidepsin Demonstrate Its Safety and Identify a Potential Role for K<sub>ATP</sub> Channel
Supplemental Tables from Electrocardiographic Studies of Romidepsin Demonstrate Its Safety and Identify a Potential Role for K<sub>ATP</sub> Channel Open
Supplemental Tables - PDF file 76K, Table S1. Diplotype arrangements of the ABCB1 SNPs calculated using Haploview. (Reproduced with authors' permission, Sissung et al, 2011(13); Table S2. Analysis of reported cardiovascular events for all …
View article: Data from Electrocardiographic Studies of Romidepsin Demonstrate Its Safety and Identify a Potential Role for K<sub>ATP</sub> Channel
Data from Electrocardiographic Studies of Romidepsin Demonstrate Its Safety and Identify a Potential Role for K<sub>ATP</sub> Channel Open
Purpose: Romidepsin is a histone deacetylase inhibitor (HDI) approved for the treatment of both cutaneous and peripheral T-cell lymphoma (CTCL and PTCL). During development, a thorough assessment of cardiac toxicity was conducted.Experimen…
View article: Supplementary Figure 2 from Electrocardiographic Studies of Romidepsin Demonstrate Its Safety and Identify a Potential Role for K<sub>ATP</sub> Channel
Supplementary Figure 2 from Electrocardiographic Studies of Romidepsin Demonstrate Its Safety and Identify a Potential Role for K<sub>ATP</sub> Channel Open
Supplementary Figure 2 - PDF file 260K, Changes in mean heart rate occurring during cycle 1 days 1, 8 and 15 grouped by baseline heart rate
View article: Supplementary Figure 1 from Electrocardiographic Studies of Romidepsin Demonstrate Its Safety and Identify a Potential Role for K<sub>ATP</sub> Channel
Supplementary Figure 1 from Electrocardiographic Studies of Romidepsin Demonstrate Its Safety and Identify a Potential Role for K<sub>ATP</sub> Channel Open
Supplementary Figure 1 - PDF file 69K, Changes in heart rate observed for patients in the NIH cohort during cycle 1 days 1, 8 and 15
View article: Supplementary Figure 3 from Electrocardiographic Studies of Romidepsin Demonstrate Its Safety and Identify a Potential Role for K<sub>ATP</sub> Channel
Supplementary Figure 3 from Electrocardiographic Studies of Romidepsin Demonstrate Its Safety and Identify a Potential Role for K<sub>ATP</sub> Channel Open
Supplementary Figure 3 - PDF file 62K, Changes in mean heart rate during cycles 1 when patients taking betablockers were excluded
View article: Supplementary Figure 8 from Electrocardiographic Studies of Romidepsin Demonstrate Its Safety and Identify a Potential Role for K<sub>ATP</sub> Channel
Supplementary Figure 8 from Electrocardiographic Studies of Romidepsin Demonstrate Its Safety and Identify a Potential Role for K<sub>ATP</sub> Channel Open
Supplementary Figure 8 - PDF file 299K, Changes in mean heart rate during cycles 2 when patients taking betablockers were excluded
View article: Supplementary Figure 4 from Electrocardiographic Studies of Romidepsin Demonstrate Its Safety and Identify a Potential Role for K<sub>ATP</sub> Channel
Supplementary Figure 4 from Electrocardiographic Studies of Romidepsin Demonstrate Its Safety and Identify a Potential Role for K<sub>ATP</sub> Channel Open
Supplementary Figure 4 - PDF file 314K, Changes in mean heart rate during cycles 1 when patients taking betablockers were excluded
View article: Supplemental Tables from Electrocardiographic Studies of Romidepsin Demonstrate Its Safety and Identify a Potential Role for K<sub>ATP</sub> Channel
Supplemental Tables from Electrocardiographic Studies of Romidepsin Demonstrate Its Safety and Identify a Potential Role for K<sub>ATP</sub> Channel Open
Supplemental Tables - PDF file 76K, Table S1. Diplotype arrangements of the ABCB1 SNPs calculated using Haploview. (Reproduced with authors' permission, Sissung et al, 2011(13); Table S2. Analysis of reported cardiovascular events for all …
View article: Supplementary Figure 6 from Electrocardiographic Studies of Romidepsin Demonstrate Its Safety and Identify a Potential Role for K<sub>ATP</sub> Channel
Supplementary Figure 6 from Electrocardiographic Studies of Romidepsin Demonstrate Its Safety and Identify a Potential Role for K<sub>ATP</sub> Channel Open
Supplementary Figure 6 - PDF file 60K, Changes in heart rate observed for each patient in the NIH cohort during cycle 2 days 1, 8 and 15, excluding the patients taking beta-blockers
View article: Supplementary Figure 2 from Electrocardiographic Studies of Romidepsin Demonstrate Its Safety and Identify a Potential Role for K<sub>ATP</sub> Channel
Supplementary Figure 2 from Electrocardiographic Studies of Romidepsin Demonstrate Its Safety and Identify a Potential Role for K<sub>ATP</sub> Channel Open
Supplementary Figure 2 - PDF file 260K, Changes in mean heart rate occurring during cycle 1 days 1, 8 and 15 grouped by baseline heart rate
View article: Supplementary Figure 7 from Electrocardiographic Studies of Romidepsin Demonstrate Its Safety and Identify a Potential Role for K<sub>ATP</sub> Channel
Supplementary Figure 7 from Electrocardiographic Studies of Romidepsin Demonstrate Its Safety and Identify a Potential Role for K<sub>ATP</sub> Channel Open
Supplementary Figure 7 - PDF file 317K, Changes in mean heart rate occurring during cycle 1 days 1, 8 and 15 grouped by baseline heart rate
View article: Supplementary Figure 7 from Electrocardiographic Studies of Romidepsin Demonstrate Its Safety and Identify a Potential Role for K<sub>ATP</sub> Channel
Supplementary Figure 7 from Electrocardiographic Studies of Romidepsin Demonstrate Its Safety and Identify a Potential Role for K<sub>ATP</sub> Channel Open
Supplementary Figure 7 - PDF file 317K, Changes in mean heart rate occurring during cycle 1 days 1, 8 and 15 grouped by baseline heart rate
View article: Supplementary Figure 4 from Electrocardiographic Studies of Romidepsin Demonstrate Its Safety and Identify a Potential Role for K<sub>ATP</sub> Channel
Supplementary Figure 4 from Electrocardiographic Studies of Romidepsin Demonstrate Its Safety and Identify a Potential Role for K<sub>ATP</sub> Channel Open
Supplementary Figure 4 - PDF file 314K, Changes in mean heart rate during cycles 1 when patients taking betablockers were excluded
View article: Data from Electrocardiographic Studies of Romidepsin Demonstrate Its Safety and Identify a Potential Role for K<sub>ATP</sub> Channel
Data from Electrocardiographic Studies of Romidepsin Demonstrate Its Safety and Identify a Potential Role for K<sub>ATP</sub> Channel Open
Purpose: Romidepsin is a histone deacetylase inhibitor (HDI) approved for the treatment of both cutaneous and peripheral T-cell lymphoma (CTCL and PTCL). During development, a thorough assessment of cardiac toxicity was conducted.Experimen…
View article: Supplementary Figure Legends from Electrocardiographic Studies of Romidepsin Demonstrate Its Safety and Identify a Potential Role for K<sub>ATP</sub> Channel
Supplementary Figure Legends from Electrocardiographic Studies of Romidepsin Demonstrate Its Safety and Identify a Potential Role for K<sub>ATP</sub> Channel Open
Supplementary Figure Legends - PDF file 25K, Legends describing supplementary figures
View article: Supplementary Figure 6 from Electrocardiographic Studies of Romidepsin Demonstrate Its Safety and Identify a Potential Role for K<sub>ATP</sub> Channel
Supplementary Figure 6 from Electrocardiographic Studies of Romidepsin Demonstrate Its Safety and Identify a Potential Role for K<sub>ATP</sub> Channel Open
Supplementary Figure 6 - PDF file 60K, Changes in heart rate observed for each patient in the NIH cohort during cycle 2 days 1, 8 and 15, excluding the patients taking beta-blockers
View article: Detection of <i>KIT</i> D816V in peripheral blood of children with manifestations of cutaneous mastocytosis suggests systemic disease
Detection of <i>KIT</i> D816V in peripheral blood of children with manifestations of cutaneous mastocytosis suggests systemic disease Open
Summary The use of allele‐specific quantitative polymerase chain reaction to identify KIT D816V in the peripheral blood of adults with mastocytosis has been reported to have value in the diagnosis, assessment of disease burden and manageme…
View article: Responses to romidepsin in patients with cutaneous T-cell lymphoma and prior treatment with systemic chemotherapy
Responses to romidepsin in patients with cutaneous T-cell lymphoma and prior treatment with systemic chemotherapy Open
Cutaneous T-cell lymphomas (CTCL) are a group of non-Hodgkin lymphomas that typically present in the skin but can progress to systemic involvement. The optimal treatment for patients who relapse from or are refractory to systemic chemother…
View article: Romidepsin is effective and well tolerated in older patients with peripheral T-cell lymphoma: analysis of two phase II trials
Romidepsin is effective and well tolerated in older patients with peripheral T-cell lymphoma: analysis of two phase II trials Open
Clinicaltrials.gov identifiers: NCT00426764, NCT00007345.
View article: Romidepsin in peripheral and cutaneous T‐cell lymphoma: mechanistic implications from clinical and correlative data
Romidepsin in peripheral and cutaneous T‐cell lymphoma: mechanistic implications from clinical and correlative data Open
Summary Romidepsin is an epigenetic agent approved for the treatment of patients with cutaneous or peripheral T‐cell lymphoma ( CTCL and PTCL ). Here we report data in all patients treated on the National Cancer Institute 1312 trial, demon…